Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem doses first patient in GFH375/VS-7375 trial
- Verastem price target lowered to $18 from $34 at Truist
- Verastem to be added to the Russell 3000 & Microcap Indexes effective July 1
- Verastem Updates Corporate Presentation with Latest Insights
- Verastem partner GenFleet says China’s NMPA approved clinical trial application